Agency
Milestone Medical Services INC
Milestone Medical Services INC was paid $6.22M by Medicaid between Jan 2018 and Dec 2024, across 83 billing codes. Its largest line is 99213, doctor's office visit, returning patient (routine) — 25% of everything it billed.
33Billing provider infoMILESTONE MEDICAL SERVICES INC
TAKOMA PARK, MD 20912
TAKOMA PARK, MD 20912
33aNPI1437412798assigned 06/21/2012
33bProvider typeHome Health Agency
28Total paid$6.22M
24GClaims176,581
24DCodes billed83
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Home Health Agency providers in Maryland
Rank by total paid#17 of 62
Median peer was paid$1.18M
This provider vs. median5.3×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 2,201 | $68K | |
| 2019 | 1,499 | $39K | |
| 2020 | 34,733 | $1.17M | |
| 2021 | 32,636 | $1.18M | |
| 2022 | 39,914 | $1.43M | |
| 2023 | 37,886 | $1.33M | |
| 2024incomplete | 27,712 | $993K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 25% | 19,914 | 16,440 | $1.58M |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 9.5% | 5,296 | 4,459 | $591K |
| 99393 | Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) | 8.5% | 5,119 | 4,717 | $527K |
| 99392 | Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) | 8.4% | 5,206 | 4,672 | $522K |
| 99391 | Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) | 7.9% | 5,969 | 4,675 | $490K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | 6.8% | 9,337 | 8,140 | $424K |
| 99394 | Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) | 6.7% | 3,662 | 3,431 | $414K |
| 96110 | Developmental screening, with scoring and documentation, per standardized instrument | 2.7% | 21,254 | 18,424 | $165K |
| 99215 | Doctor's office visit, returning patient (complex)Prolong outpt/office vis | 2.5% | 1,077 | 830 | $153K |
| 92557 | 2.4% | 4,379 | 3,986 | $147K | |
| 90733 | 2.1% | 1,448 | 1,307 | $129K | |
| 99204 | Doctor's office visit, new patient (more involved)Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity | 1.8% | 1,122 | 811 | $115K |
71 more codes
| 92551 | 1.4% | 10,425 | $86K | |
| 92081 | 1.4% | 2,955 | $85K | |
| 90670 | 1.2% | 3,165 | $72K | |
| 90686 | <1% | 2,522 | $56K | |
| 90680 | <1% | 2,577 | $48K | |
| 90698 | <1% | 2,408 | $46K | |
| 95930 | <1% | 652 | $43K | |
| 90716 | <1% | 1,878 | $41K | |
| 90633 | <1% | 1,956 | $40K | |
| 90707 | <1% | 1,870 | $39K | |
| 90677 | <1% | 654 | $38K | |
| 90651 | <1% | 1,777 | $37K | |
| 90744 | <1% | 1,833 | $35K | |
| 99177 | <1% | 6,631 | $30K | |
| 94760 | <1% | 17,510 | $24K | |
| 90697 | <1% | 889 | $24K | |
| 99395 | Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years | <1% | 183 | $21K |
| 96127 | <1% | 4,691 | $20K | |
| 90715 | <1% | 790 | $16K | |
| 90696 | <1% | 714 | $15K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 656 | $15K |
| 0071A | <1% | 363 | $13K | |
| 0072A | <1% | 334 | $12K | |
| 2015F | <1% | 1,534 | $12K | |
| 99173 | <1% | 4,271 | $8K | |
| 96161 | <1% | 4,321 | $7K | |
| 0002A | <1% | 184 | $7K | |
| 0001A | <1% | 185 | $6K | |
| 93000 | <1% | 424 | $6K | |
| 90700 | <1% | 293 | $6K | |
| 90647 | <1% | 274 | $5K | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 261 | $5K |
| 86580 | <1% | 985 | $5K | |
| 90685 | <1% | 185 | $4K | |
| 90621 | <1% | 139 | $3K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 88 | $3K |
| 90688 | <1% | 174 | $3K | |
| 3008F | <1% | 4,958 | $3K | |
| 36400 | <1% | 238 | $3K | |
| 87400 | <1% | 469 | $2K | |
| 99243 | <1% | 23 | $2K | |
| 99051 | <1% | 420 | $2K | |
| 99070 | <1% | 420 | $2K | |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 19 | $2K |
| 0240U | <1% | 27 | $1K | |
| A4558 | Conductive gel or paste, for use with electrical device (e.g., tens, nmes), per oz | <1% | 397 | $1K |
| 0004A | <1% | 15 | $600.00 | |
| 90710 | <1% | 24 | $535.44 | |
| S0316 | Disease management program, follow-up/reassessment | <1% | 29 | $517.50 |
| 90687 | <1% | 30 | $479.92 | |
| 0003A | <1% | 22 | $355.00 | |
| 97802 | <1% | 71 | $339.40 | |
| 90473 | <1% | 89 | $298.62 | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 51 | $280.43 |
| A6411 | Eye pad, non-sterile, each | <1% | 341 | $277.43 |
| S3620 | Newborn metabolic screening panel, includes test kit, postage and the laboratory tests specified by the state for inclusion in this panel (e.g., galactose; hemoglobin, electrophoresis; hydroxyprogesterone, 17-d; phenylalanine (pku); and thyroxine, total) | <1% | 459 | $219.00 |
| 99050 | <1% | 33 | $193.68 | |
| 99080 | <1% | 13 | $160.00 | |
| 90460 | Immunization administration through 18 years of age via any route, first or only component | <1% | 31 | $139.68 |
| A4556 | Electrodes, (e.g., apnea monitor), per pair | <1% | 149 | $107.70 |
| 99442 | <1% | 21 | $75.00 | |
| 1005F | <1% | 967 | $70.50 | |
| 99072 | <1% | 574 | $70.50 | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 19 | $52.96 |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 39 | $46.92 |
| 90461 | <1% | 28 | $27.50 | |
| 91307 | <1% | 366 | $24.07 | |
| 36416 | <1% | 405 | $22.53 | |
| 99000 | <1% | 1,029 | $22.50 | |
| 91300 | <1% | 220 | $15.02 | |
| INVCD | 0% | 51 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialBASSEY-AKAMUNE, FELICIA (MEDICAL DIRECTOR)